Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague‐Dawley rats and Dutch Belted rabbits
Birth Defects Research Part B: Developmental and Reproductive Toxicology · 2007-02 · 80 (1) · 57-68
DOI: 10.1002/bdrb.20104 ↗At a glance
Journal article in Birth Defects Research Part B: Developmental and Reproductive Toxicology, published online on 2007-02-09. Written by L David Wise and 2 co-authors. Institution: Merck Research Laboratories, West Point, Pennsylvania 19486, USA. ld_wise@merck.com. Major MEDLINE topics: Abnormalities, Drug-Induced, Histone Deacetylase Inhibitors. Cited 31 times so far (Crossref); 26 references.
Abstract (original language)
BACKGROUND: The developmental toxicity potential of vorinostat (suberoylanilide hydroxamic acid [SAHA], ZOLINZA™), a potent inhibitor of histone deacetylase (HDAC), was assessed in Sprague‐Dawley rats and Dutch Belted rabbits. HDAC inhibitors have been shown to mediate the regulation of gene expression, induce cell growth, cell differentiation, and apoptosis of tumor cells. Range‐finding studies established oral dose levels of 5, 15, or 50 mg/kg/day and 20, 50, or 150 mg/kg/day in rats and rabbits, respectively. METHODS: Animals were dosed on Gestation Days 6–20 or 7–20, respectively, with litter/fetal parameters evaluated on GD 21 and 28, respectively. Separate studies evaluated toxicokinetic parameters at the mid‐ and high‐dose levels. RESULTS: There was no maternal toxicity observed at the highest dose levels; however, hematology and serum biochemistry changes were characterized in the range‐finding studies. Vorinostat did not induce morphological malformations in either rat or rabbit fetuses. In rats, drug‐related developmental toxicity was observed only in the high‐dose group and consisted of markedly decreased fetal weight and increases in fetuses with a limited number of skeletal variations. In rabbits, drug‐related developmental toxicity was also observed only in the high‐dose group and consisted of slightly decreased fetal weight and increases in fetuses with a short 13th rib and incomplete ossification of metacarpals. Maternal exposures to vorinostat based on AUC and Cmax values were comparable at the high‐dose levels of both species. Rabbits tolerated higher dosages probably due to more extensive metabolism. Maternal concentrations of vorinostat were ∼1,000–fold above the known in vitro HDAC inhibitory concentration. CONCLUSIONS: Review of previous work with valproic acid, another HDAC inhibitor, suggest that the developmental toxicity profiles of these 2 compounds are not the result of HDAC inhibition but involve other mechanisms. Birth Defects Res (Part B) 80:57–68, 2007. © 2007 Wiley‐Liss, Inc.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Merck Research Laboratories, West Point, Pennsylvania 19486, USA. ld_wise@merck.com
Cite
APA
Wise, L. D., Turner, K. J., & Kerr, J. S. (2007). Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague‐Dawley rats and Dutch Belted rabbits. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 80(1), 57-68. https://doi.org/10.1002/bdrb.20104
Vancouver
Wise LD, Turner KJ, Kerr JS. Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague‐Dawley rats and Dutch Belted rabbits. Birth Defects Research Part B: Developmental and Reproductive Toxicology. 2007;80(1):57-68. doi:10.1002/bdrb.20104
BibTeX
@article{Wise2007,
author = {Wise, L David and Turner, Katie J and Kerr, Janet S},
title = {Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague‐Dawley rats and Dutch Belted rabbits},
journal = {Birth Defects Research Part B: Developmental and Reproductive Toxicology},
year = {2007},
volume = {80},
number = {1},
pages = {57--68},
doi = {10.1002/bdrb.20104}
}
EUVIMED